Food and Drug Administration Safety and Innovation Act
GPTKB entity
Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:United_States_federal_law
|
| gptkbp:abbreviation |
gptkb:FDASIA
|
| gptkbp:amendedBy |
gptkb:Federal_Food,_Drug,_and_Cosmetic_Act
|
| gptkbp:containsProvision |
gptkb:Biosimilar_User_Fee_Act
gptkb:Generic_Drug_User_Fee_Amendments gptkb:Medical_Device_User_Fee_Amendments gptkb:Pediatric_Medical_Device_Safety_and_Improvement_Act |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:dateEnacted |
July 9, 2012
|
| gptkbp:enactedBy |
gptkb:United_States_Congress
|
| https://www.w3.org/2000/01/rdf-schema#label |
Food and Drug Administration Safety and Innovation Act
|
| gptkbp:publicLawNumber |
gptkb:Public_Law_112-144
|
| gptkbp:purpose |
to reauthorize and expand user fees for drugs and medical devices
|
| gptkbp:regulates |
gptkb:Food_and_Drug_Administration
|
| gptkbp:signedBy |
gptkb:Barack_Obama
|
| gptkbp:subjectArea |
gptkb:drug
public health medical device |
| gptkbp:bfsParent |
gptkb:breakthrough_therapy_designation
|
| gptkbp:bfsLayer |
5
|